MargheRITA (Remote Intelligence for Therapeutic Adherence)

Inclusion Criteria: * Patients who understand and voluntarily sign an informed consent form (ICF) prior to any study related procedures being conducted; * Patients who are ≥ 18 years old; * Patients who are diagnosed with a onco-hematologic disease, namely: Symptomatic Multiple Myeloma, Solitary Plasmocytoma, Amyloidosis, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Hodgkin Lymphoma, B cells non-Hodgkin Lymphoma, T cells non-Hodgkin Lymphoma, Acute myeloid Leukemia, Myelodysplasia, Chronic Myeloproliferative Disorder; * Patients who receive a standard of care therapy for their disease, independently from the route of administration; * Patients in their first or subsequent line of therapy; * Patients at the beginning of the treatment, or during therapy; * Life expectancy \> 6 months. Exclusion Criteria: * Patients treated with radiotherapy only; * Presence of clinical conditions that will impair the adherence to the treatment (ie, concomitant tumor on treatment, severe neurologic disease, drug or alcohol abuse etc.); * Patient unable to use a smartphone and/or a computer (ie blindness, inability to use a smartphone or a computer etc.); * Major psychopathology or cognitive impairment likely in the judgment of the research staff to interfere with the participation or completion of the protocol; * Patient enrolled in another clinical trial.